Mark A. Smith
Chief Tech/Sci/R&D Officer at BRIGHT MINDS BIOSCIENCES INC.
Net worth: - $ as of 30/05/2024
Mark A. Smith active positions
| Companies | Position | Start | End |
|---|---|---|---|
| BRIGHT MINDS BIOSCIENCES INC. | Chief Tech/Sci/R&D Officer | 30/11/2022 | - |
Career history of Mark A. Smith
Former positions of Mark A. Smith
| Companies | Position | Start | End |
|---|---|---|---|
| VISTAGEN THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31/05/2016 | 30/11/2022 |
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 31/08/2012 | 30/09/2013 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 31/05/2000 | 31/08/2012 |
Training of Mark A. Smith
| Yale University | Graduate Degree |
| University of California San Diego | Doctorate Degree |
Statistics
International
| United States | 5 |
| United Kingdom | 3 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| VISTAGEN THERAPEUTICS, INC. | Health Technology |
| ASTRAZENECA PLC | Health Technology |
| BRIGHT MINDS BIOSCIENCES INC. | Health Technology |
| Private companies | 1 |
|---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
- Stock Market
- Insiders
- Mark A. Smith
- Experience